Neuroblastoma – Pipeline Insight and Therapeutic Assessment Reviewed in 2017

Posted on 2017-11-27 by Mark Hub in Pharmaceuticals // 0 Comments

Market Research Hub

Albany, US, 2017-Nov-27 — /EPR Network/ —A fresh report has been added to the wide database of Market Research Hub (MRH). The research study is titled “Neuroblastoma – Pipeline Review, H2 2017”which encloses important data about the production, consumption, revenue and market share, merged with information related to the market scope and product overview. The report anticipates that the sector for pharmaceutical industry would rise at a positive CAGR during the period 2017-2022.

Click here for Free Sample Report@ https://www.marketresearchhub.com/enquiry.php?type=S&repid=1381806

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Neuroblastoma – Pipeline Review, H2 2017, provides an overview of the Neuroblastoma (Oncology) pipeline landscape.

Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include lump in abdomen or chest, weakness, bone pain, breathing problems, dark circles around the eyes and difficulty in movement. The condition may be diagnosed by X-ray imaging, CT scan, MRI, biopsy, urine test, etc. It may be controlled by chemotherapy, radiation therapy, stem cell transplants and medication such as monoclonal antibody regimens.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Neuroblastoma – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 27, 20, 1, 48, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 5, 13 and 3 molecules, respectively.

Neuroblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroblastoma (Oncology).
– The pipeline guide reviews pipeline therapeutics for Neuroblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Neuroblastoma (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Neuroblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Neuroblastoma (Oncology)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Neuroblastoma (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Neuroblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Browse Full Report with TOC@ https://www.marketresearchhub.com/report/neuroblastoma-pipeline-review-h2-2017-report.html

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Neuroblastoma – Overview 10
Neuroblastoma – Therapeutics Development 11
Pipeline Overview 11
Pipeline by Companies 12
Pipeline by Universities/Institutes 17
Products under Development by Companies 20
Products under Development by Universities/Institutes 26
Neuroblastoma – Therapeutics Assessment 28
Assessment by Target 28
Assessment by Mechanism of Action 34
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Neuroblastoma – Companies Involved in Therapeutics Development 43
Ability Pharmaceuticals SL 43
Actuate Therapeutics Inc 43
Advanced Accelerator Applications SA 43
Alissa Pharma 44
Ampio Pharmaceuticals Inc 44
APAvadis Biotechnologies Srl 45
APEIRON Biologics AG 45
AstraZeneca Plc 45
Autolus Ltd 46
Bayer AG 46
Bellicum Pharmaceuticals Inc 47
Bexion Pharmaceuticals LLC 47
BioLineRx Ltd 48
Biotec Pharmacon ASA 48
Boehringer Ingelheim GmbH 49
Bristol-Myers Squibb Co 49
Cancer Prevention Pharmaceuticals Inc 49
Cebiotex SL 50
Celgene Corp 50
Celldex Therapeutics Inc 51
Cielo Therapeutics Inc 51
Cleveland BioLabs Inc 52
CorMedix Inc 52
Curis Inc 53
Cyclacel Pharmaceuticals Inc 53
DEKK-TEC Inc 54
EnGeneIC Ltd 54
Epizyme Inc 54
Errant Gene Therapeutics LLC 55
F. Hoffmann-La Roche Ltd 55
GlaxoSmithKline Plc 56
Green Cross Cell Corp 56
Ignyta Inc 57
Ipsen SA 57

Continued….

Enquire about this Report@ https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1381806

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like pharmaceutical industry reports and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick